Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy

Video Author:James P. Taylor, M.B.B.Chir., M.P.H. • Iris H. Wei, M.D. • J. Joshua Smith, M.D., Ph.D. • Amy L. Tin, M.A. • Nate Aiken, B.S. • Andrew J. Vickers, Ph.D. • Paul B. Romesser, M.D. • Christopher H. Crane, M.D. • Maria Widmar, M.D., M.P.H. • Garrett M. Nash,

Published on:November 14, 2022

A significant proportion of patients have major low anterior resection syndrome at baseline and after successful treatment for anal cancer. Having major low anterior resection syndrome at baseline was the biggest predictor of having major low anterior resection syndrome after treatment. Bowel, sexual, and urinary unction did not improve over time up to 2 years after end of treatment. Physicians should counsel their patients before treatment that baseline poor bowel function is a risk factor for posttreatment bowel dysfunction.